杏輝藥品(1734) 公告本公司原料-Lipucan茯苓萃取物應用於治療糖尿病用途獲得中國大陸專利證書。發言時間 102/04/1217:17:34發言人 樓怡美 發言人職稱 協理 發言人電話 (02)2760-3688主旨 : 公告本公司原料-Lipucan茯苓萃取物應用於治療糖尿病用途獲得中國大陸專利證書。符合條款第49款事實發生日102/04/12說明1.事實發生日:102/04/122.公司名稱:杏輝藥品工業股份有限公司3.與公司關係(請輸入本公司或子公司):本公司4.相互持股比例:不適用5.發生緣由:公告本公司原料-Lipucan(茯苓萃取物)應用於治療糖尿病用途獲得中國大陸專利證書。6.因應措施:無7.其他應敘明事項:本公司獨家研發多年的茯苓功效成分-Lipucan，除了已擁有中韓歐盟及加拿大等多國的免疫提升功效之專利外，更取得改善癌症所引起的惡病質的韓國專利及促進營養素吸收的加拿大專利並獲得台灣專利局核發改善氣喘及過敏反應功效的專利證書。本次獲得中國大陸專利證書應用於治療糖尿病用途，代表此項產品創新發明獲得更多國際肯定。以上資料均由各公司依發言當時所屬市場別之規定申報後，由本系統對外公佈，資料如有虛偽不實，均由該公司負責.
Lipucan was R&D for almost 10 years by Prof Han-Chin Lin (PhD. of National Defence Medical Center, TWN) and his term. According to the studies from Sinphar and Fu Jen University's verification and Taiwan's DOH approval, Lipucan is able to modulate immunity, activate NK cell via increasing secretion of immunocytokine IFN-γ from Th1, accelerate immune cells growth, enhance adaptive immunity, regulate secretion of interleukin, and reduce IgE, involved in allergen-induced asthma low dose may provide significant effect. The entire process from raw material collection to extraction is carried out strict control, based on ISO and cGMP standards
林漢欽 (Hang-Ching Lin) 一、學歷 學歷 學校/ 學士 台北醫學院藥學系 (57-61 年)/ 碩士 國防醫學院藥學所 藥物化學組(61-63 年)/ 博士 美國北卡羅來納大學藥學院 藥物化學及天然物學系(72-77 年)/ 二、經歷 專任(目前) 杏輝醫藥集團副研發長(91 年至今)／中草藥召集人/兼任(目前) 宜蘭大學／蘭陽技術學院／國防醫學院兼任副教授/考試院：國考命題委員/經濟部：專利審查委員(兼任)/衛生署：中醫藥委員會研究委員(兼任)/國科會／教育部：計劃審查委員(兼任)/三軍總醫院：人體實驗審查委員會委員(兼任)/(91年以前) 國防醫學院講師／副教授(專任，61-91 年)
US patent: 20100298283 PHARMACEUTICAL COMPOSITION FOR ENHANCING IMMUNITY, AND EXTRACT OF PORIA
Abstract: A pharmaceutical composition is used to enhance immunity of the human body. The composition contains potent components of lanostane compounds. A method is devised to obtain an extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The extract contains 5-60% of the lanostane compounds by weight of the extract. The extract is devoid of secolanostane capable of inhibiting immunity development.
Claims: 1. A method of enhancing immunity of an individual comprising administering to the individual a therapeutically effective amount of a lanostane having the following chemical formula (I) ##STR00005## wherein R1 is either H or CH3; R2 is OCOCH3, ═O or OH; R3 is H or OH; R4 is --C(═CH2)--C(CH3)2Ra wherein Ra is H or OH, or --CH═C(CH3)--Rb, wherein Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH. 2. The method according to claim 1, wherein the lanostane (I) is ##STR00006## 3. A method of enhancing immunity of an individual comprising administering to the individual a therapeutically effective amount of a Poria extract comprising 5-60% of a lanostane having the following chemical formula (I) by weight of the extract, and being substantially devoid of secolanostane: ##STR00007## wherein R1 is either H or CH3; R2 is OCOCH3, ═O or OH; R3 is H or OH; R4 is --C(═CH2)--C(CH3)2Ra, wherein Ra is H or OH, or --CH═C(CH3)--Rb, wherein Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH. 4. The method according to claim 3, wherein the Poria extract is prepared by a method comprising the following steps:a) extracting metabolites, fermentation products or sclerotium of Poria cocos (Schw) Wolf by water, methanol, ethanol, or a mixed solvent thereof;b) concentrating the resulting liquid extract from step a);c) introducing the resulting concentrated substance from step b) into a silica gel column;d) eluting the silica gel column with an eluent having a low polarity, and collecting the resulting eluate;e) concentrating the eluate to form a concentrated eluate. 5. The method of claim 4, wherein the concentrated eluate from step e) has a chromatographic value, Rf, not less than 0.1 in accordance with a thin layer chromatography, which is developed by a mixed solvent of dichloromethane:methanol=96:4 and is detected by an ultraviolet lamp and iodine vapor. 6. The method of claim 4, wherein the extraction in step a) is carried out by using 95% ethanol. 7. The method of claim 4, wherein the concentrated substance resulted from step b) is further extracted with a two-phase solvent containing methanol and n-hexane in a volumetric ratio of 1:1, a methanol layer is separated from the two-phase solvent extraction mixture, and the methanol layer is concentrated to form a concentrate, which is used as a feed to the silica gel column in step c). 8. The method of claim 4, wherein the low polarity eluent is a mixed solvent containing dichloromethane and methanol in a volumetric ratio of 96.5:3.5. 9. The method of claim 3, wherein the Poria extract comprises 10-20% of the lanostane (I). 10. The method of claim 3, wherein the lanostane (I) is ##STR00008##
No comments:
Post a Comment